SCHEDULE 13D/A: 23andMe Holding Co. Sells Core Assets to Affiliate TTAM Research Institute for $302.5 Million Amidst Bankruptcy

23andMe Holding Co., currently undergoing Chapter 11 bankruptcy, has agreed to sell substantially all of its assets, including its genetic testing and Lemonaid businesses, to TTAM Research Institute, an affiliate of CEO Anne Wojcicki, for $302.5 million, pending Bankruptcy Court approval.

Summary

• 23andMe Holding Co. and its subsidiaries (Sellers) have entered into an Asset Purchase Agreement with TTAM Research Institute (Purchaser), an affiliate of CEO Anne Wojcicki, to sell substantially all of their assets for $302.5 million.
• The transaction is occurring within the Sellers' Chapter 11 bankruptcy cases, which commenced on March 23, 2025, and requires approval by the U.S. Bankruptcy Court for the Eastern District of Missouri.
• The acquired assets include the direct-to-consumer genetic testing and analytics business, genomic sequencing, research services based on genetic and phenotypic information, biological samples (Industry Data), and the Lemonaid Business.
• The Purchase Price is $302,500,000, with an earnest deposit of $14,600,000, to be increased to 10% of the Purchase Price ($30,250,000).
• TTAM Research Institute was declared the winning bidder in the auction for the Issuer's assets on June 13, 2025.
• The agreement outlines specific Assumed Liabilities (e.g., post-closing contract performance, Cure Amounts up to a cap, customer deposits) and Excluded Liabilities (e.g., pre-petition indebtedness, certain taxes, pre-closing litigation).
• The Lemonaid Business is excluded from the main asset sale but TTAM agrees to serve as a stalking horse sponsor for a separate Chapter 11 plan to acquire the reorganized equity interests in the Lemonaid Entities for $2.5 million, or the Purchase Price will increase by $2.5 million if TTAM elects to wind down the Lemonaid Business.
• TTAM has cash accounts exceeding $330,000,000 and a Grant Commitment Letter from Anne Wojcicki and related entities to ensure sufficient funds for the acquisition.

Sentiment

Score: 3

Explanation: The sentiment is negative for the public company (23andMe Holding Co.) as it is undergoing bankruptcy and selling substantially all of its assets, indicating severe financial distress and likely minimal or no value for existing shareholders. While the sale provides a resolution for the business operations and ensures continuity under a new (related) entity, it represents a significant loss for the original investors. The positive aspects are primarily for the acquired business and its customers under the new ownership, rather than for the selling public company's shareholders.

Positives

• Secures a buyer for substantially all of 23andMe's assets, providing a path forward for the business operations amidst bankruptcy.
• The sale price of $302.5 million provides a significant recovery for the bankruptcy estate.
• The purchaser, TTAM Research Institute, is an affiliate of CEO Anne Wojcicki, suggesting continuity and commitment to the core business.
• Purchaser has demonstrated strong financial capacity with over $330 million in cash and a grant commitment letter from Anne Wojcicki and her affiliates.
• The agreement includes specific consumer protection and privacy safeguards, such as adherence to existing privacy policies, restrictions on data sharing with insurance companies, and a commitment not to share data with entities from 'Countries of Concern'.
• TTAM commits to establishing a Consumer Privacy Advisory Board and providing regular compliance reports, enhancing transparency and consumer trust.
• Transferred Employees will receive comparable base salary/wage, cash incentive opportunities, and retirement/health/welfare benefits for 12 months post-closing.
• The agreement includes a provision for 2 years of complimentary identity theft monitoring for customers, addressing potential concerns from past security incidents.

Negatives

• The sale of 'substantially all assets' indicates a significant restructuring or potential liquidation of the public entity, 23andMe Holding Co., which is in Chapter 11 bankruptcy.
• The transaction is subject to Bankruptcy Court approval, which introduces uncertainty and potential delays, especially given 'State Objections' and 'Adversary Proceedings' mentioned.
• The 'Plan Toggle' provision indicates a contingency where the sale might shift from a direct asset sale to a Chapter 11 plan, potentially complicating the process.
• The Lemonaid Business is subject to a separate, smaller transaction ($2.5 million) and potential higher offers, or even a wind-down, adding complexity and uncertainty to that segment.
• The document highlights a '2023 Security Incident' and related investigations, indicating past data privacy challenges that could impact the business's reputation or future operations.
• The 'Excluded Liabilities' section is extensive, meaning many of the company's existing financial and legal burdens will remain with the selling entity, potentially impacting creditors or remaining shareholders.
• The 'No Survival' clause for most representations and warranties post-closing limits recourse for the buyer, except in cases of Fraud or Willful Breach.

Risks

• Bankruptcy Court Approval Risk: The transaction is subject to the Bankruptcy Court's approval via a Sale Order, and there are 'State Objections' and 'Adversary Proceedings' that could lead to denial or delays.
• Regulatory Approval Risk: While HSR is stated as not required for the buyer, other governmental or regulatory approvals might be needed, and failure to obtain them could impede or delay closing.
• Litigation Risk: Ongoing or threatened litigation related to the 2023 Security Incident or IP infringement by Sellers could impact the business or its value, as these are largely Excluded Liabilities.
• Data Privacy Compliance Risk: Despite safeguards, future compliance with evolving Privacy Laws and managing customer data (especially genetic data) remains a significant operational and reputational risk.
• Employee Transition Risk: While offers are extended, ensuring a smooth transition and retention of key Transferred Employees is crucial for business continuity.
• Lemonaid Business Uncertainty: The separate process for the Lemonaid Business, including potential higher offers or a wind-down, introduces uncertainty for that segment.
• Integration Risk: For the buyer, integrating the acquired assets and operations, especially data and IT systems, carries inherent risks.
• Financial Risk for Sellers: The extensive list of Excluded Liabilities means the selling entity retains significant financial and legal burdens post-sale, impacting the bankruptcy estate and its creditors.

Future Outlook

The document primarily focuses on the asset sale within bankruptcy, rather than a forward-looking business outlook for the selling entity. However, it indicates that TTAM Research Institute intends to operate the acquired business in a manner consistent with 23andMe's historical operations, with 'nonprofit-related limitations for more narrow research.' It also outlines commitments for future data privacy compliance and the potential acquisition of the Lemonaid Business via a separate Chapter 11 plan.

Management Comments

• Each Seller has determined, in the exercise of its business judgment, that the sale to Purchaser as contemplated herein is the highest or otherwise best bid for the Acquired Assets, and therefore it is advisable and in the best interest of the estates and the beneficiaries of their estates to enter into this Agreement and to consummate the transactions contemplated hereby, which has been approved by such Sellers applicable governing body.
• Purchaser acknowledges and agrees that notwithstanding anything to the contrary contained herein, its obligation to consummate the transactions contemplated hereby is not subject to Purchaser or any of its Affiliates (including the Grantors) obtaining any financing.
• Purchaser knows of no circumstance or condition that could be reasonably expected to prevent the availability of the Grant at Closing or upon termination of such funds.
• Purchaser expects to extend an offer of employment to all such Business Employees on compensation and benefits terms substantially similar to their current terms.

Industry Context

This transaction occurs within the highly competitive and regulated genetic testing and digital health industries. The sale of 23andMe's core assets, including its extensive genetic and phenotypic data, to a related non-profit entity (TTAM Research Institute, an affiliate of CEO Anne Wojcicki) during bankruptcy proceedings is a notable event. It suggests a strategic shift or consolidation, potentially aiming to leverage the data for more focused research under a non-profit structure, which could differentiate it from other for-profit competitors in the direct-to-consumer genetic testing space (e.g., AncestryDNA, MyHeritage DNA). The emphasis on consumer privacy safeguards, particularly regarding genetic data and insurance companies, reflects increasing regulatory scrutiny and consumer concerns in the health data sector. The separate treatment of the Lemonaid telehealth business indicates a potential divestiture or restructuring of that segment, which operates in the broader telehealth market alongside players like Teladoc, Amwell, and MDLive.

Comparison to Industry Standards

• Data Privacy: TTAM's commitment to retain 23andMe's current policies on data deletion and opt-out rights, and not to sell/share genetic data with insurance companies without explicit authorization, sets a high standard for consumer protection, potentially exceeding some industry practices, especially given the sensitive nature of genetic data. The establishment of a Consumer Privacy Advisory Board and regular reporting to State Attorneys General are proactive measures that go beyond typical industry compliance.
• Bankruptcy Asset Sales: The sale process, including the auction and 'stalking horse' bid for Lemonaid, is standard practice in Chapter 11 bankruptcies for maximizing asset value and ensuring a fair process. The 'free and clear' transfer of assets is a common outcome in such sales.
• Related Party Transactions: The acquisition by an affiliate of the CEO (Anne Wojcicki) is a related-party transaction. While common, it often draws increased scrutiny from regulators and stakeholders to ensure fairness and best interests of the bankruptcy estate. The document emphasizes the 'highest or otherwise best bid' determination by Sellers, which is a standard justification in such scenarios.
• Employee Transition: Offering comparable compensation and benefits for 12 months to transferred employees is a reasonable practice to ensure continuity and morale during an acquisition, aligning with industry standards for employee retention in M&A.

Management Changes

Corporate Governance

Legal Proceedings

• Sellers commenced Chapter 11 Bankruptcy Cases on March 23, 2025 (Case No. 25-40976-357) in the United States Bankruptcy Court for the Eastern District of Missouri.
• There are 'State Objections' and 'Adversary Proceedings' filed by objecting states related to the Sale, which could impact the Bankruptcy Court's approval.
• The document references a '2023 Security Incident' that led to past or pending litigation, arbitration, Action or proceeding, with related liabilities largely excluded from the sale.
• Pending 'Cure/Assignment Objections' exist regarding the amount of Cure Amounts owing under Transferred Contracts.

Related Party Transactions

• The Purchaser, TTAM Research Institute, is explicitly stated as an 'affiliate of Ms. Wojcicki, the LLC and the Trust.'
• Anne Wojcicki is the CEO and President of TTAM Research Institute.
• Anne Wojcicki, ABeeC 2.0, LLC, AW Aqua LLC, and THE ANNE WOJCICKI REVOCABLE TRUST U/A/D 9/2/09, AS AMENDED AND RESTATED (collectively, the Grantors) are providing an 'irrevocable and unconditional grant of funds' to TTAM Research Institute to finance the acquisition.
• Anne Wojcicki is a significant beneficial owner of 23andMe Holding Co. Class A Common Stock (22%).
• The sale is described as being to the 'highest or otherwise best bid,' despite the related-party nature, implying an arm's-length process within the bankruptcy framework.

Stakeholder Impact

• Shareholders (23andMe Holding Co.): Highly negative impact. The sale of 'substantially all assets' in bankruptcy typically results in minimal or no recovery for equity holders, as creditors are prioritized.
• Employees (Business Employees): Mixed impact. Purchaser will extend employment offers with comparable compensation and benefits for 12 months to 'Offer Employees,' providing continuity for those who transfer. However, Sellers are responsible for WARN Act liabilities for non-transferred employees, indicating potential layoffs for some.
• Customers: Mixed to positive impact. The business operations are expected to continue under TTAM. Strong consumer protection and privacy safeguards are explicitly outlined, including data deletion rights, restrictions on sharing genetic data with insurers, and a Consumer Privacy Advisory Board, which could enhance trust. Two years of complimentary identity theft monitoring is offered.
• Creditors (23andMe Holding Co.): The $302.5 million purchase price will be used to satisfy claims in bankruptcy. The extensive 'Excluded Liabilities' mean many debts remain with the selling entity, impacting the recovery for various creditor classes.
• Suppliers/Vendors: Transferred Contracts will be assumed by the Purchaser, ensuring continuity for those relationships. Cure Amounts will be paid for assumed contracts.

Next Steps

• Obtain Bankruptcy Court approval of the Asset Purchase Agreement and entry of the Sale Order.
• Satisfy all closing conditions outlined in Article IX of the agreement.
• Purchaser to make additional earnest deposit to reach 10% of Purchase Price.
• Sellers to file Schedule of Transferred Contracts with the Bankruptcy Court.
• Sellers and Purchaser to cooperate in obtaining necessary consents and regulatory approvals (if any).
• Purchaser to extend offers of employment to Business Employees.
• Purchaser to establish a Consumer Privacy Advisory Board within 90 days following the Closing Date.
• TTAM to prepare and file reports on privacy compliance and customer issues every 6-12 months for at least three years.
• TTAM to offer 2 years of complimentary identity theft monitoring to customers.
• Sellers to cease using and displaying acquired trademarks and Excluded Marks post-closing.
• Sellers and Purchaser to cooperate on the Lemonaid Plan Transaction, aiming for Bankruptcy Court confirmation by November 15, 2025, or wind-down the Lemonaid Business.
• Sellers to issue WARN Act notices to Business Employees no later than 60 days prior to Closing Date.

Key Dates

Keywords

23andMe, TTAM Research Institute, Asset Purchase Agreement, Bankruptcy, Chapter 11, Genetic Testing, Genomic Sequencing, Lemonaid Health, Direct-to-Consumer, Healthcare, Biotechnology, Data Privacy, SEC Filing, Schedule 13D, Corporate Restructuring, Acquisition, Anne Wojcicki, Consumer Health, Research Services